Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...
Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...
Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...
Lilly said it is taking legal action against medical spas, wellness centers and compounding pharmacies that sell products purported to contain tirzepatide. The new online program Lilly launched ...
Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
It is tailored to patients being treated with Lilly's oncology drugs – which ... than 30 DiGAs that have approved for use by the BfArM medical regulator and are covered by the national GKV ...
Over the course of 72 weeks, Lilly tested Zepbound and Wegovy on a population of adults with obesity or patients with "at least one weight-related medical problem and without diabetes." ...
surpassing the Medical sector's loss of 6.22% and falling behind the S&P 500's loss of 1.7%. Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure.
Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he ...